Diabetes Care:CVD占糖尿病患者死因半壁江山(大庆研究23年随访结果)

2015-04-21 中国医学论坛报 刘娟编译

北京阜外医院李光伟教授团队的最新研究表明,糖尿病与中国成人死亡率增加相关, CVD是主要死因,其中卒中引起的死亡几乎占半数。文章4月17日在线发表于《糖尿病护理》(Diabetes Care)杂志。研究者对比了1986年大庆研究中从110 660例受试者中筛选出来的新诊断为糖尿病者(NDD,630例)与正常糖耐量者(NGT,519例)的死亡率和死因,受试者年龄为25~74岁。结果显示,2

北京阜外医院李光伟教授团队的最新研究表明,糖尿病与中国成人死亡率增加相关, CVD是主要死因,其中卒中引起的死亡几乎占半数。文章4月17日在线发表于《糖尿病护理》(Diabetes Care)杂志。

研究者对比了1986年大庆研究中从110 660例受试者中筛选出来的新诊断为糖尿病者(NDD,630例)与正常糖耐量者(NGT,519例)的死亡率和死因,受试者年龄为25~74岁。

结果显示,23年随访期间,共338名(56.5%)NDD受试者和100名(20.3%)NGT受试者死亡。CVD是以上受试者的主要死亡原因(男性中占47.5%,女性中占49.7%),其中几乎有一半死于卒中(男性中占52.3%,女性中占42.3%)。NDD组年龄校正的全因死亡率为NGT者的3倍(男性:36.9%对13.3%;女性:27.1%对9.2%。P<0.0001)。在NDD组,CVD死亡率未见性别差异(男性17.5%对女性13.5%),肾脏病和感染增加死亡率。

原始出处:
An Y, Zhang P, Wang J, Gong Q, Gregg EW, Yang W, Li H, Zhang B, Shuai Y, Chen Y, Engelgau MM, Cheng Y, Hu Y, Bennett PH, Li G.Cardiovascular and All-Cause Mortality Over a 23-Year Period Among Chinese With Newly Diagnosed Diabetes in the Da Qing IGT and Diabetes Study. Diabetes Care. 2015 Apr 17. pii: dc142498.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (10)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1901284, encodeId=89e8190128463, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Wed Aug 26 01:21:00 CST 2015, time=2015-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1759545, encodeId=67781e59545e9, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Tue Jun 30 10:21:00 CST 2015, time=2015-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1818763, encodeId=67151818e6301, content=<a href='/topic/show?id=9687984e5e3' target=_blank style='color:#2F92EE;'>#随访结果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98475, encryptionId=9687984e5e3, topicName=随访结果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sun Dec 20 10:21:00 CST 2015, time=2015-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1650671, encodeId=40c916506e1ef, content=<a href='/topic/show?id=36f143e0901' target=_blank style='color:#2F92EE;'>#大庆研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43709, encryptionId=36f143e0901, topicName=大庆研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=53e424082391, createdName=songbq, createdTime=Sun Jan 10 21:21:00 CST 2016, time=2016-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=26905, encodeId=c21b26905d0, content=赞一个赞一个, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ac181616815, createdName=ljjj1053, createdTime=Wed Jun 10 16:34:00 CST 2015, time=2015-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1637079, encodeId=98e4163e0796e, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Thu Apr 23 02:21:00 CST 2015, time=2015-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=22749, encodeId=9b5622e49d0, content=一项让人佩服的研究!, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=qingfengqishi5, createdTime=Wed May 06 14:32:00 CST 2015, time=2015-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=21833, encodeId=ee602183352, content=抄袭!本文为“中国医学论坛报今日糖尿病“微信公众号4月21日原创文章,贵网站转载完全不注明出处及作者,限你们24小时内删除文章,否则将依法追责。, beContent=null, objectType=article, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8c761622703, createdName=heisenangua, createdTime=Fri Apr 24 00:25:00 CST 2015, time=2015-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=21745, encodeId=cae621e45c7, content=临床常见, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63461620684, createdName=yuena, createdTime=Thu Apr 23 10:59:00 CST 2015, time=2015-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1473862, encodeId=d8cc14e3862ba, content=<a href='/topic/show?id=935fe6718e3' target=_blank style='color:#2F92EE;'>#糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76718, encryptionId=935fe6718e3, topicName=糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a38f7243741, createdName=xue8604, createdTime=Thu Apr 23 10:21:00 CST 2015, time=2015-04-23, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1901284, encodeId=89e8190128463, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Wed Aug 26 01:21:00 CST 2015, time=2015-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1759545, encodeId=67781e59545e9, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Tue Jun 30 10:21:00 CST 2015, time=2015-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1818763, encodeId=67151818e6301, content=<a href='/topic/show?id=9687984e5e3' target=_blank style='color:#2F92EE;'>#随访结果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98475, encryptionId=9687984e5e3, topicName=随访结果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sun Dec 20 10:21:00 CST 2015, time=2015-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1650671, encodeId=40c916506e1ef, content=<a href='/topic/show?id=36f143e0901' target=_blank style='color:#2F92EE;'>#大庆研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43709, encryptionId=36f143e0901, topicName=大庆研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=53e424082391, createdName=songbq, createdTime=Sun Jan 10 21:21:00 CST 2016, time=2016-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=26905, encodeId=c21b26905d0, content=赞一个赞一个, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ac181616815, createdName=ljjj1053, createdTime=Wed Jun 10 16:34:00 CST 2015, time=2015-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1637079, encodeId=98e4163e0796e, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Thu Apr 23 02:21:00 CST 2015, time=2015-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=22749, encodeId=9b5622e49d0, content=一项让人佩服的研究!, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=qingfengqishi5, createdTime=Wed May 06 14:32:00 CST 2015, time=2015-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=21833, encodeId=ee602183352, content=抄袭!本文为“中国医学论坛报今日糖尿病“微信公众号4月21日原创文章,贵网站转载完全不注明出处及作者,限你们24小时内删除文章,否则将依法追责。, beContent=null, objectType=article, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8c761622703, createdName=heisenangua, createdTime=Fri Apr 24 00:25:00 CST 2015, time=2015-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=21745, encodeId=cae621e45c7, content=临床常见, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63461620684, createdName=yuena, createdTime=Thu Apr 23 10:59:00 CST 2015, time=2015-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1473862, encodeId=d8cc14e3862ba, content=<a href='/topic/show?id=935fe6718e3' target=_blank style='color:#2F92EE;'>#糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76718, encryptionId=935fe6718e3, topicName=糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a38f7243741, createdName=xue8604, createdTime=Thu Apr 23 10:21:00 CST 2015, time=2015-04-23, status=1, ipAttribution=)]
    2015-06-30 仁医06
  3. [GetPortalCommentsPageByObjectIdResponse(id=1901284, encodeId=89e8190128463, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Wed Aug 26 01:21:00 CST 2015, time=2015-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1759545, encodeId=67781e59545e9, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Tue Jun 30 10:21:00 CST 2015, time=2015-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1818763, encodeId=67151818e6301, content=<a href='/topic/show?id=9687984e5e3' target=_blank style='color:#2F92EE;'>#随访结果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98475, encryptionId=9687984e5e3, topicName=随访结果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sun Dec 20 10:21:00 CST 2015, time=2015-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1650671, encodeId=40c916506e1ef, content=<a href='/topic/show?id=36f143e0901' target=_blank style='color:#2F92EE;'>#大庆研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43709, encryptionId=36f143e0901, topicName=大庆研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=53e424082391, createdName=songbq, createdTime=Sun Jan 10 21:21:00 CST 2016, time=2016-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=26905, encodeId=c21b26905d0, content=赞一个赞一个, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ac181616815, createdName=ljjj1053, createdTime=Wed Jun 10 16:34:00 CST 2015, time=2015-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1637079, encodeId=98e4163e0796e, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Thu Apr 23 02:21:00 CST 2015, time=2015-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=22749, encodeId=9b5622e49d0, content=一项让人佩服的研究!, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=qingfengqishi5, createdTime=Wed May 06 14:32:00 CST 2015, time=2015-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=21833, encodeId=ee602183352, content=抄袭!本文为“中国医学论坛报今日糖尿病“微信公众号4月21日原创文章,贵网站转载完全不注明出处及作者,限你们24小时内删除文章,否则将依法追责。, beContent=null, objectType=article, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8c761622703, createdName=heisenangua, createdTime=Fri Apr 24 00:25:00 CST 2015, time=2015-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=21745, encodeId=cae621e45c7, content=临床常见, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63461620684, createdName=yuena, createdTime=Thu Apr 23 10:59:00 CST 2015, time=2015-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1473862, encodeId=d8cc14e3862ba, content=<a href='/topic/show?id=935fe6718e3' target=_blank style='color:#2F92EE;'>#糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76718, encryptionId=935fe6718e3, topicName=糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a38f7243741, createdName=xue8604, createdTime=Thu Apr 23 10:21:00 CST 2015, time=2015-04-23, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1901284, encodeId=89e8190128463, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Wed Aug 26 01:21:00 CST 2015, time=2015-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1759545, encodeId=67781e59545e9, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Tue Jun 30 10:21:00 CST 2015, time=2015-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1818763, encodeId=67151818e6301, content=<a href='/topic/show?id=9687984e5e3' target=_blank style='color:#2F92EE;'>#随访结果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98475, encryptionId=9687984e5e3, topicName=随访结果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sun Dec 20 10:21:00 CST 2015, time=2015-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1650671, encodeId=40c916506e1ef, content=<a href='/topic/show?id=36f143e0901' target=_blank style='color:#2F92EE;'>#大庆研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43709, encryptionId=36f143e0901, topicName=大庆研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=53e424082391, createdName=songbq, createdTime=Sun Jan 10 21:21:00 CST 2016, time=2016-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=26905, encodeId=c21b26905d0, content=赞一个赞一个, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ac181616815, createdName=ljjj1053, createdTime=Wed Jun 10 16:34:00 CST 2015, time=2015-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1637079, encodeId=98e4163e0796e, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Thu Apr 23 02:21:00 CST 2015, time=2015-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=22749, encodeId=9b5622e49d0, content=一项让人佩服的研究!, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=qingfengqishi5, createdTime=Wed May 06 14:32:00 CST 2015, time=2015-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=21833, encodeId=ee602183352, content=抄袭!本文为“中国医学论坛报今日糖尿病“微信公众号4月21日原创文章,贵网站转载完全不注明出处及作者,限你们24小时内删除文章,否则将依法追责。, beContent=null, objectType=article, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8c761622703, createdName=heisenangua, createdTime=Fri Apr 24 00:25:00 CST 2015, time=2015-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=21745, encodeId=cae621e45c7, content=临床常见, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63461620684, createdName=yuena, createdTime=Thu Apr 23 10:59:00 CST 2015, time=2015-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1473862, encodeId=d8cc14e3862ba, content=<a href='/topic/show?id=935fe6718e3' target=_blank style='color:#2F92EE;'>#糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76718, encryptionId=935fe6718e3, topicName=糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a38f7243741, createdName=xue8604, createdTime=Thu Apr 23 10:21:00 CST 2015, time=2015-04-23, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1901284, encodeId=89e8190128463, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Wed Aug 26 01:21:00 CST 2015, time=2015-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1759545, encodeId=67781e59545e9, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Tue Jun 30 10:21:00 CST 2015, time=2015-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1818763, encodeId=67151818e6301, content=<a href='/topic/show?id=9687984e5e3' target=_blank style='color:#2F92EE;'>#随访结果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98475, encryptionId=9687984e5e3, topicName=随访结果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sun Dec 20 10:21:00 CST 2015, time=2015-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1650671, encodeId=40c916506e1ef, content=<a href='/topic/show?id=36f143e0901' target=_blank style='color:#2F92EE;'>#大庆研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43709, encryptionId=36f143e0901, topicName=大庆研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=53e424082391, createdName=songbq, createdTime=Sun Jan 10 21:21:00 CST 2016, time=2016-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=26905, encodeId=c21b26905d0, content=赞一个赞一个, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ac181616815, createdName=ljjj1053, createdTime=Wed Jun 10 16:34:00 CST 2015, time=2015-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1637079, encodeId=98e4163e0796e, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Thu Apr 23 02:21:00 CST 2015, time=2015-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=22749, encodeId=9b5622e49d0, content=一项让人佩服的研究!, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=qingfengqishi5, createdTime=Wed May 06 14:32:00 CST 2015, time=2015-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=21833, encodeId=ee602183352, content=抄袭!本文为“中国医学论坛报今日糖尿病“微信公众号4月21日原创文章,贵网站转载完全不注明出处及作者,限你们24小时内删除文章,否则将依法追责。, beContent=null, objectType=article, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8c761622703, createdName=heisenangua, createdTime=Fri Apr 24 00:25:00 CST 2015, time=2015-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=21745, encodeId=cae621e45c7, content=临床常见, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63461620684, createdName=yuena, createdTime=Thu Apr 23 10:59:00 CST 2015, time=2015-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1473862, encodeId=d8cc14e3862ba, content=<a href='/topic/show?id=935fe6718e3' target=_blank style='color:#2F92EE;'>#糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76718, encryptionId=935fe6718e3, topicName=糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a38f7243741, createdName=xue8604, createdTime=Thu Apr 23 10:21:00 CST 2015, time=2015-04-23, status=1, ipAttribution=)]
    2015-06-10 ljjj1053

    赞一个赞一个

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1901284, encodeId=89e8190128463, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Wed Aug 26 01:21:00 CST 2015, time=2015-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1759545, encodeId=67781e59545e9, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Tue Jun 30 10:21:00 CST 2015, time=2015-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1818763, encodeId=67151818e6301, content=<a href='/topic/show?id=9687984e5e3' target=_blank style='color:#2F92EE;'>#随访结果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98475, encryptionId=9687984e5e3, topicName=随访结果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sun Dec 20 10:21:00 CST 2015, time=2015-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1650671, encodeId=40c916506e1ef, content=<a href='/topic/show?id=36f143e0901' target=_blank style='color:#2F92EE;'>#大庆研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43709, encryptionId=36f143e0901, topicName=大庆研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=53e424082391, createdName=songbq, createdTime=Sun Jan 10 21:21:00 CST 2016, time=2016-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=26905, encodeId=c21b26905d0, content=赞一个赞一个, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ac181616815, createdName=ljjj1053, createdTime=Wed Jun 10 16:34:00 CST 2015, time=2015-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1637079, encodeId=98e4163e0796e, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Thu Apr 23 02:21:00 CST 2015, time=2015-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=22749, encodeId=9b5622e49d0, content=一项让人佩服的研究!, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=qingfengqishi5, createdTime=Wed May 06 14:32:00 CST 2015, time=2015-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=21833, encodeId=ee602183352, content=抄袭!本文为“中国医学论坛报今日糖尿病“微信公众号4月21日原创文章,贵网站转载完全不注明出处及作者,限你们24小时内删除文章,否则将依法追责。, beContent=null, objectType=article, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8c761622703, createdName=heisenangua, createdTime=Fri Apr 24 00:25:00 CST 2015, time=2015-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=21745, encodeId=cae621e45c7, content=临床常见, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63461620684, createdName=yuena, createdTime=Thu Apr 23 10:59:00 CST 2015, time=2015-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1473862, encodeId=d8cc14e3862ba, content=<a href='/topic/show?id=935fe6718e3' target=_blank style='color:#2F92EE;'>#糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76718, encryptionId=935fe6718e3, topicName=糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a38f7243741, createdName=xue8604, createdTime=Thu Apr 23 10:21:00 CST 2015, time=2015-04-23, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1901284, encodeId=89e8190128463, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Wed Aug 26 01:21:00 CST 2015, time=2015-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1759545, encodeId=67781e59545e9, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Tue Jun 30 10:21:00 CST 2015, time=2015-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1818763, encodeId=67151818e6301, content=<a href='/topic/show?id=9687984e5e3' target=_blank style='color:#2F92EE;'>#随访结果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98475, encryptionId=9687984e5e3, topicName=随访结果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sun Dec 20 10:21:00 CST 2015, time=2015-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1650671, encodeId=40c916506e1ef, content=<a href='/topic/show?id=36f143e0901' target=_blank style='color:#2F92EE;'>#大庆研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43709, encryptionId=36f143e0901, topicName=大庆研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=53e424082391, createdName=songbq, createdTime=Sun Jan 10 21:21:00 CST 2016, time=2016-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=26905, encodeId=c21b26905d0, content=赞一个赞一个, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ac181616815, createdName=ljjj1053, createdTime=Wed Jun 10 16:34:00 CST 2015, time=2015-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1637079, encodeId=98e4163e0796e, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Thu Apr 23 02:21:00 CST 2015, time=2015-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=22749, encodeId=9b5622e49d0, content=一项让人佩服的研究!, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=qingfengqishi5, createdTime=Wed May 06 14:32:00 CST 2015, time=2015-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=21833, encodeId=ee602183352, content=抄袭!本文为“中国医学论坛报今日糖尿病“微信公众号4月21日原创文章,贵网站转载完全不注明出处及作者,限你们24小时内删除文章,否则将依法追责。, beContent=null, objectType=article, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8c761622703, createdName=heisenangua, createdTime=Fri Apr 24 00:25:00 CST 2015, time=2015-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=21745, encodeId=cae621e45c7, content=临床常见, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63461620684, createdName=yuena, createdTime=Thu Apr 23 10:59:00 CST 2015, time=2015-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1473862, encodeId=d8cc14e3862ba, content=<a href='/topic/show?id=935fe6718e3' target=_blank style='color:#2F92EE;'>#糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76718, encryptionId=935fe6718e3, topicName=糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a38f7243741, createdName=xue8604, createdTime=Thu Apr 23 10:21:00 CST 2015, time=2015-04-23, status=1, ipAttribution=)]
    2015-05-06 qingfengqishi5

    一项让人佩服的研究!

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=1901284, encodeId=89e8190128463, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Wed Aug 26 01:21:00 CST 2015, time=2015-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1759545, encodeId=67781e59545e9, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Tue Jun 30 10:21:00 CST 2015, time=2015-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1818763, encodeId=67151818e6301, content=<a href='/topic/show?id=9687984e5e3' target=_blank style='color:#2F92EE;'>#随访结果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98475, encryptionId=9687984e5e3, topicName=随访结果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sun Dec 20 10:21:00 CST 2015, time=2015-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1650671, encodeId=40c916506e1ef, content=<a href='/topic/show?id=36f143e0901' target=_blank style='color:#2F92EE;'>#大庆研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43709, encryptionId=36f143e0901, topicName=大庆研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=53e424082391, createdName=songbq, createdTime=Sun Jan 10 21:21:00 CST 2016, time=2016-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=26905, encodeId=c21b26905d0, content=赞一个赞一个, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ac181616815, createdName=ljjj1053, createdTime=Wed Jun 10 16:34:00 CST 2015, time=2015-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1637079, encodeId=98e4163e0796e, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Thu Apr 23 02:21:00 CST 2015, time=2015-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=22749, encodeId=9b5622e49d0, content=一项让人佩服的研究!, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=qingfengqishi5, createdTime=Wed May 06 14:32:00 CST 2015, time=2015-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=21833, encodeId=ee602183352, content=抄袭!本文为“中国医学论坛报今日糖尿病“微信公众号4月21日原创文章,贵网站转载完全不注明出处及作者,限你们24小时内删除文章,否则将依法追责。, beContent=null, objectType=article, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8c761622703, createdName=heisenangua, createdTime=Fri Apr 24 00:25:00 CST 2015, time=2015-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=21745, encodeId=cae621e45c7, content=临床常见, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63461620684, createdName=yuena, createdTime=Thu Apr 23 10:59:00 CST 2015, time=2015-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1473862, encodeId=d8cc14e3862ba, content=<a href='/topic/show?id=935fe6718e3' target=_blank style='color:#2F92EE;'>#糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76718, encryptionId=935fe6718e3, topicName=糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a38f7243741, createdName=xue8604, createdTime=Thu Apr 23 10:21:00 CST 2015, time=2015-04-23, status=1, ipAttribution=)]
    2015-04-24 heisenangua

    抄袭!本文为“中国医学论坛报今日糖尿病“微信公众号4月21日原创文章,贵网站转载完全不注明出处及作者,限你们24小时内删除文章,否则将依法追责。

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=1901284, encodeId=89e8190128463, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Wed Aug 26 01:21:00 CST 2015, time=2015-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1759545, encodeId=67781e59545e9, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Tue Jun 30 10:21:00 CST 2015, time=2015-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1818763, encodeId=67151818e6301, content=<a href='/topic/show?id=9687984e5e3' target=_blank style='color:#2F92EE;'>#随访结果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98475, encryptionId=9687984e5e3, topicName=随访结果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sun Dec 20 10:21:00 CST 2015, time=2015-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1650671, encodeId=40c916506e1ef, content=<a href='/topic/show?id=36f143e0901' target=_blank style='color:#2F92EE;'>#大庆研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43709, encryptionId=36f143e0901, topicName=大庆研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=53e424082391, createdName=songbq, createdTime=Sun Jan 10 21:21:00 CST 2016, time=2016-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=26905, encodeId=c21b26905d0, content=赞一个赞一个, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ac181616815, createdName=ljjj1053, createdTime=Wed Jun 10 16:34:00 CST 2015, time=2015-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1637079, encodeId=98e4163e0796e, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Thu Apr 23 02:21:00 CST 2015, time=2015-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=22749, encodeId=9b5622e49d0, content=一项让人佩服的研究!, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=qingfengqishi5, createdTime=Wed May 06 14:32:00 CST 2015, time=2015-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=21833, encodeId=ee602183352, content=抄袭!本文为“中国医学论坛报今日糖尿病“微信公众号4月21日原创文章,贵网站转载完全不注明出处及作者,限你们24小时内删除文章,否则将依法追责。, beContent=null, objectType=article, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8c761622703, createdName=heisenangua, createdTime=Fri Apr 24 00:25:00 CST 2015, time=2015-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=21745, encodeId=cae621e45c7, content=临床常见, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63461620684, createdName=yuena, createdTime=Thu Apr 23 10:59:00 CST 2015, time=2015-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1473862, encodeId=d8cc14e3862ba, content=<a href='/topic/show?id=935fe6718e3' target=_blank style='color:#2F92EE;'>#糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76718, encryptionId=935fe6718e3, topicName=糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a38f7243741, createdName=xue8604, createdTime=Thu Apr 23 10:21:00 CST 2015, time=2015-04-23, status=1, ipAttribution=)]
    2015-04-23 yuena

    临床常见

    0

  10. [GetPortalCommentsPageByObjectIdResponse(id=1901284, encodeId=89e8190128463, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Wed Aug 26 01:21:00 CST 2015, time=2015-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1759545, encodeId=67781e59545e9, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Tue Jun 30 10:21:00 CST 2015, time=2015-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1818763, encodeId=67151818e6301, content=<a href='/topic/show?id=9687984e5e3' target=_blank style='color:#2F92EE;'>#随访结果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98475, encryptionId=9687984e5e3, topicName=随访结果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sun Dec 20 10:21:00 CST 2015, time=2015-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1650671, encodeId=40c916506e1ef, content=<a href='/topic/show?id=36f143e0901' target=_blank style='color:#2F92EE;'>#大庆研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43709, encryptionId=36f143e0901, topicName=大庆研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=53e424082391, createdName=songbq, createdTime=Sun Jan 10 21:21:00 CST 2016, time=2016-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=26905, encodeId=c21b26905d0, content=赞一个赞一个, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ac181616815, createdName=ljjj1053, createdTime=Wed Jun 10 16:34:00 CST 2015, time=2015-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1637079, encodeId=98e4163e0796e, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Thu Apr 23 02:21:00 CST 2015, time=2015-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=22749, encodeId=9b5622e49d0, content=一项让人佩服的研究!, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=qingfengqishi5, createdTime=Wed May 06 14:32:00 CST 2015, time=2015-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=21833, encodeId=ee602183352, content=抄袭!本文为“中国医学论坛报今日糖尿病“微信公众号4月21日原创文章,贵网站转载完全不注明出处及作者,限你们24小时内删除文章,否则将依法追责。, beContent=null, objectType=article, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8c761622703, createdName=heisenangua, createdTime=Fri Apr 24 00:25:00 CST 2015, time=2015-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=21745, encodeId=cae621e45c7, content=临床常见, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63461620684, createdName=yuena, createdTime=Thu Apr 23 10:59:00 CST 2015, time=2015-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1473862, encodeId=d8cc14e3862ba, content=<a href='/topic/show?id=935fe6718e3' target=_blank style='color:#2F92EE;'>#糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76718, encryptionId=935fe6718e3, topicName=糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a38f7243741, createdName=xue8604, createdTime=Thu Apr 23 10:21:00 CST 2015, time=2015-04-23, status=1, ipAttribution=)]

相关资讯

PLOS ONE:WC与BMI联用能更好的评估CMD和CVD风险

心血管疾病(CVD)是影响中国人健康最普遍的疾病,可以预料的是心脏代谢紊乱(CMD)和CVD一起将成为更加严重的公共健康负担。肥胖作为心脏代谢最重要的危险因素,在过去20年期间,中国人肥胖的发病率一路飙升。为了更新中国成年人肥胖的发病率,评估在中国成年人,单独和联合使用腰围(WC)和体重指数(BMI)指标增量识别CMD和CVA风险的临床效果,来自中国国家糖尿病和代谢紊乱研究组的贾伟平教授等人进行了

JCEM:25(OH)D水平或可反应心血管疾病风险

多项研究提示低血清25–羟维生素D[25(OH)D]浓度与高心血管疾病(CVD)风险有关,但这方面的证据仍不确定,多数证据基于CVD死亡率,且研究中的25(OH)D测量方法单一。为在同一的研究人群中通过重复测量25(OH)D并分析竞争风险,以评估25(OH)D与致命性和非致命性CVD的关系,来自德国癌症研究中心的Laura Perna教授及其团队进行了一项研究,发现低25(OH)D水平与CVD风险

Diabetes Care:低血糖与室性心率失常风险增高有关

在2型糖尿病合并心血管疾病(CVD)的患者中,胰岛素和/或磺酰脲类强化治疗可能与低血糖事件风险过度升高相关。为了评价危险的心律失常与血糖变异性的相关性,来自卡尔。古斯塔夫。卡鲁斯大学医院的Stahn博士等对2型糖尿病合并CVD患者进行了一项观察性研究。研究发现,严重低血糖事件与严重室性心率失常风险增高有关。研究结果在线发表于2013年9月16日的美国《糖尿病治疗》(

medscape:CAD患者,性别差异造成影响不同

新的研究结果表明,由于男性和女性的生理心理不同,患者对于稳定性心绞痛(CAD)产生的精神压力不同。这个结论一旦被确认,将解释为什么患CAD的女性的状况比男性差,这将为风险评估和治疗提供新观点。 在经过3项压力测试后,患有CAD的男性相对于女性,在血压和其他传统危险因素方面更有可能发生变化。但患有CAD的女性心脏血流灌注减少(精神压力造成的心肌缺血);女性也更易产生胶原刺激引起的血小板聚集;同时,

JAMA Intern Med:男性大量补钙或致心脏病死亡风险升高

    美国学者的一项研究表明,男性大量补钙与其心血管疾病(CVD)死亡风险增加相关。论文2013年2月4日在线发表于《美国医学会杂志·内科学》(JAMA Intern Med)。   研究共纳入38万多名50~71岁的受试者。在平均12年随访期间,与不补钙者相比,男性补充性钙摄入超过1000 mg/d与CVD死亡风险升高相关[相对危险(RR)=1.20

Int J Cardiol:阜外医院医生发现代谢异常的正常体重人群心血管风险升高

研究要点: 1.阜外医院张伟丽等人对肥胖和代谢异常共同对心血管疾病风险和死亡率之间的联系做了研究。 2.研究结果发现体重正常但代谢异常的人群心血管风险升高,健康的超重和肥胖人群风险也增加。人们以往认为代谢正常的健康肥胖是一种良性状态,但本次研究结果对此提出了质疑。 3.研究结果发表在《国际心血管杂志》上。 体重正常、超重和肥胖的人群由于代谢异